Stock listing
NASDAQ:TELO Telomir Pharmaceuticals, Inc. Stock
Home listing (NASDAQ) of Telomir Pharmaceuticals, Inc.
Follow Telomir Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:TELO
$0.364 USD -0.056 (-13.4%)
Close on Nov 20, 2026
- Day range
- $0.358 – $0.437 USDNov 20, 2026
- Volume
- 255,911 sharesNov 20, 2026
- Market cap
- $26.82M USDAt the close on Nov 20, 2026 · price × 73.68M shares outstanding
- 52-week range
- $0.358 – $1.580 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $111,939 USDMedian day 64,200 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:TELO · Home | $0.364 USD | -0.056 (-13.4%) | 255,911 | $0.430 | $0.437 | $0.358 | $0.421 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:TELO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.364 | -0.056 | -13.4% | $0.430 | $0.437 | $0.358 | 255,911 | |
| $0.421 | -0.003 | -0.6% | $0.448 | $0.448 | $0.420 | 151,191 | |
| $0.423 | -0.058 | -12.0% | $0.468 | $0.500 | $0.401 | 326,017 | |
| $0.481 | -0.010 | -2.0% | $0.474 | $0.517 | $0.446 | 481,515 | |
| $0.491 | -0.010 | -2.0% | $0.492 | $0.572 | $0.488 | 124,262 | |
| $0.500 | -0.095 | -15.9% | $0.595 | $0.630 | $0.470 | 228,612 | |
| $0.595 | +0.023 | +4.0% | $0.587 | $0.710 | $0.573 | 321,147 | |
| $0.572 | -0.118 | -17.1% | $0.690 | $0.699 | $0.545 | 431,670 | |
| $0.690 | -0.020 | -2.8% | $0.710 | $0.730 | $0.670 | 170,630 | |
| $0.710 | -0.070 | -9.0% | $0.775 | $0.820 | $0.693 | 152,252 | |
| $0.780 | -0.095 | -10.8% | $0.832 | $0.870 | $0.780 | 166,377 | |
| $0.875 | -0.035 | -3.8% | $0.910 | $0.930 | $0.855 | 235,434 | |
| $0.910 | -0.005 | -0.6% | $0.940 | $0.950 | $0.910 | 54,234 | |
| $0.915 | -0.020 | -2.1% | $0.940 | $0.960 | $0.907 | 58,043 | |
| $0.935 | -0.029 | -3.0% | $0.960 | $0.990 | $0.791 | 96,698 | |
| $0.964 | -0.046 | -4.5% | $0.980 | $1.010 | $0.962 | 115,058 | |
| $1.010 | -0.010 | -1.0% | $1.000 | $1.050 | $0.980 | 44,535 | |
| $1.020 | +0.021 | +2.2% | $1.030 | $1.070 | $1.010 | 53,982 | |
| $0.999 | +0.024 | +2.4% | $1.000 | $1.045 | $0.975 | 41,887 | |
| $0.975 | -0.035 | -3.5% | $0.980 | $0.990 | $0.960 | 48,800 | |
| $1.010 | -0.010 | -1.0% | $1.030 | $1.030 | $0.970 | 93,400 | |
| $1.020 | +0.010 | +1.0% | $1.010 | $1.060 | $1.010 | 37,700 | |
| $1.010 | -0.030 | -2.9% | $1.020 | $1.050 | $1.000 | 78,000 | |
| $1.040 | -0.010 | -1.0% | $1.050 | $1.099 | $1.030 | 29,200 | |
| $1.050 | 0.000 | 0.0% | $1.040 | $1.130 | $1.040 | 39,200 | |
| $1.050 | 0.000 | 0.0% | $1.040 | $1.070 | $1.010 | 69,300 | |
| $1.050 | -0.040 | -3.7% | $1.100 | $1.105 | $1.030 | 86,900 | |
| $1.090 | -0.010 | -0.9% | $1.100 | $1.200 | $1.075 | 53,800 | |
| $1.100 | -0.020 | -1.8% | $1.130 | $1.140 | $1.090 | 70,900 | |
| $1.120 | -0.030 | -2.6% | $1.160 | $1.160 | $1.100 | 64,600 | |
| $1.150 | +0.030 | +2.7% | $1.110 | $1.150 | $1.100 | 131,500 | |
| $1.120 | -0.080 | -6.7% | $1.160 | $1.170 | $1.120 | 124,500 | |
| $1.200 | -0.010 | -0.8% | $1.250 | $1.580 | $1.170 | 1,253,700 | |
| $1.210 | +0.030 | +2.5% | $1.240 | $1.270 | $1.190 | 134,400 | |
| $1.180 | +0.010 | +0.9% | $1.170 | $1.220 | $1.170 | 74,100 | |
| $1.170 | -0.030 | -2.5% | $1.200 | $1.220 | $1.150 | 59,700 | |
| $1.200 | +0.030 | +2.6% | $1.190 | $1.240 | $1.170 | 43,300 | |
| $1.170 | -0.030 | -2.5% | $1.190 | $1.200 | $1.160 | 34,300 | |
| $1.200 | -0.030 | -2.4% | $1.235 | $1.235 | $1.170 | 72,100 | |
| $1.230 | +0.020 | +1.7% | $1.220 | $1.230 | $1.200 | 56,000 | |
| $1.210 | -0.010 | -0.8% | $1.210 | $1.240 | $1.210 | 31,100 | |
| $1.220 | -0.030 | -2.4% | $1.240 | $1.245 | $1.210 | 34,600 | |
| $1.250 | +0.010 | +0.8% | $1.250 | $1.290 | $1.210 | 103,200 | |
| $1.240 | +0.010 | +0.8% | $1.230 | $1.245 | $1.190 | 46,400 | |
| $1.230 | +0.110 | +9.8% | $1.150 | $1.300 | $1.130 | 480,500 | |
| $1.120 | -0.010 | -0.9% | $1.180 | $1.240 | $1.100 | 146,400 | |
| $1.130 | -0.040 | -3.4% | $1.144 | $1.169 | $1.130 | 37,700 | |
| $1.170 | 0.000 | 0.0% | $1.160 | $1.179 | $1.140 | 27,200 | |
| $1.170 | 0.000 | 0.0% | $1.120 | $1.198 | $1.115 | 50,000 | |
| $1.170 | -0.010 | -0.8% | $1.180 | $1.208 | $1.110 | 33,100 | |
| $1.180 | -0.040 | -3.3% | $1.190 | $1.220 | $1.175 | 32,500 | |
| $1.220 | +0.030 | +2.5% | $1.190 | $1.230 | $1.180 | 32,100 | |
| $1.190 | +0.030 | +2.6% | $1.140 | $1.230 | $1.130 | 74,900 | |
| $1.160 | 0.000 | 0.0% | $1.170 | $1.190 | $1.160 | 33,900 | |
| $1.160 | +0.040 | +3.6% | $1.120 | $1.170 | $1.110 | 64,200 | |
| $1.120 | +0.020 | +1.8% | $1.110 | $1.130 | $1.089 | 31,400 | |
| $1.100 | -0.020 | -1.8% | $1.130 | $1.130 | $1.085 | 19,600 | |
| $1.120 | -0.020 | -1.8% | $1.110 | $1.140 | $1.080 | 45,400 | |
| $1.140 | -0.050 | -4.2% | $1.200 | $1.200 | $1.140 | 38,200 | |
| $1.190 | +0.020 | +1.7% | $1.160 | $1.200 | $1.145 | 130,200 | |
| $1.170 | -0.010 | -0.8% | $1.170 | $1.200 | $1.141 | 69,000 | |
| $1.180 | +0.010 | +0.9% | $1.180 | $1.196 | $1.156 | 40,500 | |
| $1.170 | +0.040 | +3.5% | $1.130 | $1.200 | $1.130 | 56,400 | |
| $1.130 | 0.000 | 0.0% | $1.130 | $1.160 | $1.110 | 43,300 | |
| $1.130 | -0.040 | -3.4% | $1.180 | $1.180 | $1.110 | 35,300 |
- Ticker
- NASDAQ:TELO
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 18, 2026
Telomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer
Latest deck · July 2026
Investor Presentation (July 2026)
Investor deck · 25 slides
Latest news
Telomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer
Nov 18, 2026
Closed $0.421 (-0.6%) on Nov 18, 2026
Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company
Oct 6, 2026
Closed $1.20 (-0.8%) on Oct 6, 2026
Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)
Sep 17, 2026
Closed $1.12 (-0.9%) on Sep 17, 2026
Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models
Sep 14, 2026
Closed $1.17 (0.0%) on Sep 14, 2026
Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models
Aug 10, 2026
Closed $1.17 (+0.9%) on Aug 10, 2026
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model
Jun 15, 2026
Closed $1.29 (+2.4%) on Jun 15, 2026
Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease
May 20, 2026
Closed $1.31 (+7.4%) on May 20, 2026
Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer
Apr 30, 2026
Closed $1.40 (-3.4%) on Apr 30, 2026
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1
Apr 27, 2026
Closed $1.42 (+1.4%) on Apr 27, 2026
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)
Apr 24, 2026
Closed $1.40 (+1.4%) on Apr 24, 2026
Telomir Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 15 in the last 12 months · 58 in all · newest Nov 18, 2026 · oldest 2024
- Decks
- 9 decks · latest July 2026
Where Telomir Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:TELO · Home listing · This page | NASDAQ | United States | USD |
| BOATS:TELO | BOATS | United States | USD |
Valuation
Price/book 6.1× against a median of 1.9×: 9th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $22.30M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 6.1×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.74
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Telomir Pharmaceuticals, Inc. · NASDAQ:TELO | US$26.82M | US$22.30M | n/a | n/a | n/a | 6.1× | n/a | 0.0× | 1.74 |
| Holy Stone Healthcare Co., Ltd. · TPEX:4194 | US$27.49M | US$25.08M | n/a | n/a | n/a | 7.3× | n/a | 0.0× | n/a |
| SoftOx Solutions AS · OSL:SOFTX | US$27.28M | US$25.25M | n/a | n/a | n/a | 11.6× | n/a | 0.0× | n/a |
| Edesa Biotech, Inc. · NASDAQ:EDSA | US$27.02M | US$16.72M | n/a | n/a | n/a | 3.1× | n/a | 0.0× | 0.47 |
| Amplia Therapeutics Ltd. · ASX:ATX | US$26.86M | US$8.64M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | n/a |
| Nasus Pharma Ltd. · AMEX:NSRX | US$26.82M | US$15.11M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 0.99 |
| BriaCell Therapeutics Corp · TSX:BCT | US$26.79M | US$6.25M | n/a | n/a | n/a | 1.7× | n/a | 0.0× | 1.07 |
| Alterity Therapeutics Ltd. · ASX:ATH | US$26.78M | US$2.18M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | n/a |
| EyePoint, Inc. · NASDAQ:EYPT | US$26.65M | −US$72.44M | n/a | −28.1× | n/a | 0.3× | n/a | 0.2× | 1.36 |
| Aprogen, Inc · KRX:007460 | US$26.64M | US$21.32M | n/a | 0.2× | n/a | 0.6× | −60.1% | 0.6× | n/a |
| PolTREG Spolka Akcyjna · GPW:PTG | US$26.08M | US$22.34M | n/a | 378× | n/a | 2.2× | n/a | 0.1× | n/a |
| Median of the others | US$26.81M | US$15.92M | 0.2× | 1.9× | −60.1% | 0.0× | 1.03 |
Forecasts
1 buy · Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.
- Price target
- 4.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.11 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Erez Aminov | Chairman and Chief Executive Officer |
| Andriy Mushak | Chief Financial Officer |
Board
| Director | Role |
|---|---|
| Erez Aminov | Chairman and Chief Executive Officer |
| Matthew P. Del Giudice | Director |
| Matthew Pratt Whalen | Director |
| Ned MacPherson | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 6, 2026 · After close | −2.8% |
| Q2 2026 | Aug 13, 2026 | −1.8% |
| Q1 2026 | May 12, 2026 · After close | −2.4% |
| Q4 2025 | Feb 25, 2026 | +8.3% |
| Q3 2025 | Nov 10, 2025 · After close | +3.6% |
| Q2 2025 | Aug 14, 2025 · After close | −5.1% |
| Q1 2025 | May 14, 2025 · After close | −11.3% |
| Q4 2024 | Feb 4, 2025 · After close | +3.2% |
| Q3 2024 | Nov 11, 2024 · After close | −4.3% |
| Q2 2024 | Aug 13, 2024 · After close | −15.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (July 2026) | Investor deck | 25 slides | July 2026 |
| Investor Presentation (April 2026) | Investor deck | 43 slides | April 2026 |
| Investor Presentation (February 2026) | Investor deck | 70 slides | February 2026 |
| Investor Presentation (November 2025) | Investor deck | 63 slides | November 2025 |
| Bio Presentation (June 2025) | Conference | 30 slides | June 2025 |
| Investor Presentation (February 2025) | Investor deck | 28 slides | February 2025 |
| Investor Presentation (January 2025) | Investor deck | 28 slides | January 2025 |
| Investor Presentation (August 2024) | Investor deck | 27 slides | August 2024 |
| Corporate Update (April 2024) | Corporate update | 31 slides | Apr 15, 2024 |
Financings
| Raise | Date |
|---|---|
| Private placement of common stock Announced: about US$5.6M · US$1.16 a share · Alexander Capital, L.P. Dealers: Alexander Capital, L.P. (lead) Buyers: John Paul DeJoria (additional $1.0 million investment) Use of proceeds: Clinical development of Telomir-Zn, including its Phase 1/2 program in advanced or metastatic TNBC, plus working capital and general corporate purposes | Oct 6, 2026 |
| Capital contributions from former TELI shareholders Closed: US$1M raised Buyers: Certain former TELI shareholders ($1.0 million funded at closing; up to an additional $4.0 million in milestone-based contributions) | Apr 27, 2026 |
| Milestone shares of common stock Announced: up to US$5M Buyers: certain TELI shareholders (up to $5 million in cash or cash equivalents: $1 million at closing, $2 million upon IND acceptance, $2 million upon Phase 1/2 initiation) Use of proceeds: To advance development of Telomir-1 | Oct 21, 2025 |
| Strategic investment of restricted shares of common stock Closed: US$3M raised · US$3 a share Buyers: The Bayshore Trust (1 million restricted shares at $3.00 per share for $3 million) Insiders: Purchased entirely by The Bayshore Trust, the Company's largest shareholder Use of proceeds: Fund Telomir-1's upcoming IND submission for a rare disease indication and strengthen the balance sheet | May 21, 2025 |
| Strategic investment of common stock Closed: US$1M in the latest tranche · US$7 a share Buyers: The Starwood Trust ($1 million in common stock at $7 per share) Use of proceeds: To advance its scientific research and product development activities | Dec 17, 2024 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$7.00 a share on Feb 8, 2024.
- Price
- US$7.00 a share
- Shares offered
- 1,000,000 shares of common stock
- Offering size
- US$7 million
- Underwriters' option
- Up to 150,000 more shares
- Listing
- TELO on the Nasdaq Capital Market
- Underwriter
- Kingswood Investments
- Shares delivered
- On or about Feb 13, 2024
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 14, 2023 |
| Filed publicly | Nov 14, 2023 |
| Amended 3 times | Newest Jan 3, 2024 |
| Shares registered with an exchange | Feb 6, 2024 |
| Declared effective by the SEC | Feb 8, 2024 |
| Final prospectus, with the price | Feb 12, 2024 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 12, 2024 |
| 424B1 · Prospectus | Feb 12, 2024 |
| EFFECT · Notice that a registration is effective | Feb 8, 2024 |
| CERT · Exchange's certificate of listing | Feb 8, 2024 |
| 8-A12B · Registration of shares for listing on an exchange | Feb 6, 2024 |
| CORRESP · Letter to the SEC | Feb 6, 2024 |
| CORRESP · Letter to the SEC | Feb 6, 2024 |
| CORRESP · Letter to the SEC | Jan 3, 2024 |
| S-1/A · Registration statement, amended | Jan 3, 2024 |
| UPLOAD · Letter from the SEC | Dec 19, 2023 |
All 21 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Dec 19, 2023 |
| CORRESP · Letter to the SEC | Dec 14, 2023 |
| S-1/A · Registration statement, amended | Dec 14, 2023 |
| UPLOAD · Letter from the SEC | Nov 28, 2023 |
| S-1 · Registration statement | Nov 14, 2023 |
| CORRESP · Letter to the SEC | Nov 13, 2023 |
| UPLOAD · Letter from the SEC | Nov 1, 2023 |
| DRSLTR · Letter to the SEC with a draft | Oct 16, 2023 |
| DRS/A · Draft registration statement, amended | Oct 16, 2023 |
| UPLOAD · Letter from the SEC | Sep 18, 2023 |
| DRS · Draft registration statement | Aug 14, 2023 |
Open IPO · From the cover of the final prospectus (424B1) filed Feb 12, 2024
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2025 | FY2024 | FY2024 | FY2023 | FY2023 | FY2022 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | ||||
| Cost of revenue | 3.94M | ||||||||
| Gross profit | -3.94M | ||||||||
| Research and development | 2.44M | 2.44M | 2.24M | 2.24M | 1.57M | 1.57M | 833.2K | 833.2K | 126.5K |
| Selling, general and administrative | 8.10M | 9.64M | 600.2K | 20.9K | 11.6K | ||||
| Operating income | -10.5M | -12.2M | -3.94M | -854.1K | -138.1K | ||||
| Depreciation and amortization | 4.34M | 1.61M | 854.1K | 138.1K | |||||
| EBITDA | -7.90M | -2.33M | 0 | 0 | |||||
| Interest expense | 0 | 4.34M | 4.34M | 1.64M | 1.64M | 0 | |||
| Income before tax | -10.4M | -16.5M | -13.1M | -854.1K | -138.1K | ||||
| Income tax | -16.5M | -2.30M | -854.1K | -138.1K | |||||
| Net income | -10.4M | -10.4M | -16.5M | -16.5M | -13.1M | -13.1M | -854.1K | -854.1K | -138.1K |
| Earnings per share, basic | -0.33 | -0.33 | -0.56 | -0.56 | 0.48 | -0.44 | -0.03 | -0.03 | -0.00 |
| Earnings per share, diluted | -0.33 | -0.56 | 0.48 | -0.03 |
Balance sheet
| Line | FY2025 | FY2025 | FY2024 | FY2024 | FY2023 | FY2023 | FY2022 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 7.29M | 7.29M | 1.27M | 1.27M | 1.23K | 1.23K | 1.42K | 1.42K | 0 |
| Receivables | 130.0K | ||||||||
| Inventory | 303.3K | ||||||||
| Current assets | 7.34M | 7.34M | 1.32M | 1.32M | 435.2K | 435.2K | 48.7K | 1.42K | 0 |
| Total assets | 7.34M | 7.34M | 1.32M | 1.32M | 4.77M | 4.77M | 48.7K | 48.7K | 55.0K |
| Accounts payable | 536.8K | 587.5K | 707.2K | 404.2K | 18.7K | ||||
| Current liabilities | 1.43M | 1.43M | 681.0K | 681.0K | 1.34M | 1.34M | 986.0K | 986.0K | 138.1K |
| Total debt | 473.8K | 93.4K | 101.0K | 581.8K | 119.4K | ||||
| Total liabilities | 1.43M | 1.43M | 681.0K | 681.0K | 1.34M | 1.34M | 986.0K | 986.0K | 138.1K |
| Shareholders' equity | 5.91M | 5.91M | 643.0K | 643.0K | 3.44M | 3.44M | -937.3K | -937.3K | -83.1K |
| Shares outstanding | 34.4M | 31.7M | 29.8M | 29.5M | 28.6M | 29.6M | 26.8M | 29.6M | 29.6M |
Cash flow
| Line | FY2025 | FY2025 | FY2024 | FY2024 | FY2023 | FY2023 | FY2022 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -3.69M | -3.69M | -5.07M | -5.07M | -3.86M | -3.86M | -468.7K | -468.7K | -119.4K |
| Capital spending | 0 | 0 | -4 | 0 | -4 | ||||
| Free cash flow | -3.69M | -5.07M | -3.86M | -468.7K | -119.4K | ||||
| Cash from financing | 9.71M | 9.71M | 6.34M | 6.34M | 3.86M | 3.86M | 470.1K | 470.1K | 119.4K |
| Change in cash | 6.02M | 6.02M | 1.26M | 1.26M | -188 | -188 | 1.42K | 1.42K | 0 |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 18, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Nov 6, 2026 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Nov 6, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Nov 5, 2026 | Offer document | SEC |
| S-3 · Registration statement | Oct 27, 2026 | Offer document | SEC |
| 8-K · Current report | Oct 6, 2026 | Material contract | SEC |
| 8-K · Current report | Sep 17, 2026 | Current report | SEC |
| 8-K · Current report | Sep 16, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Sep 14, 2026 | Current report | SEC |
| DEFA14A · Additional proxy material | Aug 19, 2026 | Meeting notice | SEC |
All 151 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2026 | Current report | SEC |
| DEF 14A · Proxy statement | Jul 28, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Jul 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 27, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 15, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Jun 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 8, 2026 | Management or board change | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 8-K · Current report | May 20, 2026 | Current report | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | Apr 30, 2026 | Current report | SEC |
| 4 · Change in ownership | Apr 24, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 24, 2026 | Acquisition or disposal | SEC |
| 8-K · Current report | Mar 31, 2026 | Current report | SEC |
| 8-K · Current report | Mar 31, 2026 | Current report | SEC |
| 8-K · Current report | Mar 27, 2026 | Management or board change | SEC |
| 10-K · Annual report | Mar 17, 2026 | Annual report | SEC |
| DEFM14A | Feb 19, 2026 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Feb 19, 2026 | Meeting notice | SEC |
| 8-K · Current report | Feb 17, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 5, 2026 | Current report | SEC |
| PRER14A | Feb 4, 2026 | Other filings | SEC |
| PRER14A | Jan 23, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 9, 2026 | Current report | SEC |
| 8-K · Current report | Jan 5, 2026 | Current report | SEC |
| 8-K · Current report | Dec 19, 2025 | Management or board change | SEC |
| 8-K · Current report | Dec 17, 2025 | Current report | SEC |
| PRER14A | Nov 28, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 24, 2025 | Current report | SEC |
| 8-K · Current report | Nov 20, 2025 | Management or board change | SEC |
| PREM14A | Nov 20, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 20, 2025 | Current report | SEC |
| 8-K · Current report | Nov 12, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 10, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 22, 2025 | Current report | SEC |
| 8-K · Current report | Oct 20, 2025 | Material contract | SEC |
| 8-K · Current report | Oct 14, 2025 | Current report | SEC |
| 8-K · Current report | Oct 8, 2025 | Current report | SEC |
| 8-K · Current report | Oct 6, 2025 | Current report | SEC |
| 3 · Initial statement of ownership | Oct 3, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 18, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 18, 2025 | Current report | SEC |
| 8-K · Current report | Sep 9, 2025 | Current report | SEC |
| 8-K · Current report | Sep 4, 2025 | Current report | SEC |
| 8-K · Current report | Aug 27, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Current report | SEC |
| 8-K · Current report | Jul 23, 2025 | Current report | SEC |
| 8-K · Current report | Jul 22, 2025 | Current report | SEC |
| 8-K · Current report | Jul 17, 2025 | Current report | SEC |
| 8-K · Current report | Jun 18, 2025 | Current report | SEC |
| 8-K · Current report | Jun 11, 2025 | Current report | SEC |
| 3 · Initial statement of ownership | Jun 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 5, 2025 | Current report | SEC |
| 8-K · Current report | Jun 2, 2025 | Current report | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| 8-K · Current report | May 29, 2025 | Current report | SEC |
| 8-K · Current report | May 21, 2025 | Material contract | SEC |
| 8-K · Current report | May 21, 2025 | Financing | SEC |
| 8-K · Current report | May 15, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2025 | Current report | SEC |
| 8-K · Current report | Mar 19, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Mar 3, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 26, 2025 | Other filings | SEC |
| 8-K · Current report | Feb 25, 2025 | Current report | SEC |
| 8-K · Current report | Feb 20, 2025 | Current report | SEC |
| UPLOAD · Letter from the SEC | Feb 20, 2025 | Other filings | SEC |
| 8-K · Current report | Feb 18, 2025 | Current report | SEC |
| S-3 · Registration statement | Feb 14, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 4, 2025 | Annual report | SEC |
| 5 · Annual statement of ownership | Feb 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 28, 2025 | Current report | SEC |
| 8-K · Current report | Jan 7, 2025 | Current report | SEC |
| 8-K · Current report | Dec 23, 2024 | Current report | SEC |
| 8-K · Current report | Dec 20, 2024 | Current report | SEC |
| 8-K · Current report | Dec 11, 2024 | Financing | SEC |
| 8-K · Current report | Dec 2, 2024 | Current report | SEC |
| 4 · Change in ownership | Nov 25, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 21, 2024 | Management or board change | SEC |
| 8-K · Current report | Nov 20, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Sep 27, 2024 | Material contract | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 3, 2024 | Current report | SEC |
| 4 · Change in ownership | Aug 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 29, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 15, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 15, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 15, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 15, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jun 21, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | May 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Apr 15, 2024 | Current report | SEC |
| 8-K · Current report | Apr 12, 2024 | Management or board change | SEC |
| 10-K · Annual report | Mar 29, 2024 | Annual report | SEC |
| 4 · Change in ownership | Feb 15, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 13, 2024 | Material contract | SEC |
| 424B4 · Prospectus | Feb 12, 2024 | Offer document | SEC |
| 424B1 · Prospectus | Feb 12, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Feb 9, 2024 | Other filings | SEC |
| 3 · Initial statement of ownership | Feb 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 8, 2024 | Insider trade | SEC |
| CERT · Exchange's certificate of listing | Feb 8, 2024 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Feb 6, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 6, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 6, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 3, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jan 3, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Dec 19, 2023 | Other filings | SEC |
| S-1/A · Registration statement, amended | Dec 19, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | Dec 14, 2023 | Other filings | SEC |
| S-1/A · Registration statement, amended | Dec 14, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Nov 28, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 13, 2023 | Other filings | SEC |
| S-1 · Registration statement | Nov 13, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Nov 1, 2023 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Oct 16, 2023 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Oct 16, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Sep 18, 2023 | Other filings | SEC |
| DRS · Draft registration statement | Aug 14, 2023 | Offer document | SEC |
| D | Apr 3, 2023 | Other filings | SEC |
Cap table
Built by 6ix from Telomir Pharmaceuticals, Inc.’s releases · as of Nov 5, 2026
- Common shares
- 73,675,706
- Fully diluted
- 73,675,706
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 73,675,706 | Nov 5, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 5, 2026 | 73,675,706 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Christopher C Chapman Jr Other companies: MIRA Pharmaceuticals, Inc. (Executive Chairman, Director · Aug 2, 2023 – Aug 17, 2023 · Past); Q/C Technologies, Inc. (President, Chief Med. Officer, Director · Apr 16, 2021 – Jun 7, 2023 · Past); Rock Creek Pharmaceuticals Inc (President, Director · Sep 22, 2006 – Dec 27, 2013 · Past) | CEO & Chairman, Director · Feb 8, 2024 – Feb 8, 2024 · Past |
| Craig Eagle Other companies: OS Therapies Incorporated (Director · Since at least Jul 1, 2026); Guardant Health, Inc. (Chief Medical Officer · Since at least May 4, 2021); Q/C Technologies, Inc. (Director · Apr 16, 2021 – Jun 7, 2023 · Past) | Director · Feb 8, 2024 – Feb 8, 2024 · Past |
| Michael Jerman Other companies: Alaunos Therapeutics, Inc. (Managing Partner of Hollywell Partners · Since at least Jul 15, 2025); Inhibitor Therapeutics Inc. (Director · Since at least Apr 1, 2024); MIRA Pharmaceuticals, Inc. (Director · Nov 14, 2023 – Mar 25, 2024 · Past) | Director · Feb 8, 2024 – Aug 27, 2024 · Past |
| Alan Weichselbaum Other companies: FinWise Bancorp (Director · Since at least Oct 6, 2022); MIRA Pharmaceuticals, Inc. (Chief Financial Officer · May 15, 2025 – May 15, 2025 · Past) | Chief Financial Officer · May 15, 2025 – May 15, 2025 · Past |
| Hugh McColl III Other companies: Westrock Coffee Company (Director · Since at least Aug 26, 2022); MIRA Pharmaceuticals, Inc. (Director · Aug 2, 2023 – Aug 2, 2023 · Past) | Director · Feb 8, 2024 – Feb 8, 2024 · Past |
| Michelle Yanez Other companies: Inhibitor Therapeutics Inc. (Director · Since at least Dec 13, 2022); MIRA Pharmaceuticals, Inc. (Chief Financial Officer · Aug 2, 2023 – Dec 9, 2024 · Past) | Chief Financial Officer · Jun 18, 2024 – Aug 27, 2024 · Past |
| Andriy Mushak Other companies: MIRA Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Jun 2, 2026) | Chief Financial Officer · Since at least Jun 3, 2026 |
| Bradley Kroenig Other companies: MIRA Pharmaceuticals, Inc. (Director · Aug 2, 2023 – Aug 2, 2023 · Past) | Director · Feb 8, 2024 – Feb 8, 2024 · Past |
| Christos Nicholoudis Other companies: MIRA Pharmaceuticals, Inc. (Director · Aug 2, 2023 – Aug 17, 2023 · Past) | General Counsel, Director · Feb 8, 2024 – Feb 8, 2024 · Past |
| Edward Clouston MacPherson Other companies: MIRA Pharmaceuticals, Inc. (Director · Since at least Mar 13, 2024) | Director · Since at least Aug 8, 2024 |
All 16 people
| Person | Seat |
|---|---|
| Erez Aminov Other companies: MIRA Pharmaceuticals, Inc. (Chairman of the Board and Chief Executive Officer · Since at least Aug 2, 2023) | Chairman and Chief Executive Officer · Since at least Aug 8, 2024 |
| Matthew Del Giudice Other companies: MIRA Pharmaceuticals, Inc. (Director · Since at least Mar 13, 2024) | Director · Since at least Aug 8, 2024 |
| Matthew Pratt Whalen Other companies: MIRA Pharmaceuticals, Inc. (Director · Since at least Nov 18, 2024) | Director · Since at least Aug 8, 2024 |
| Nathen Fuentes Other companies: Lunai Bioworks Inc. (Chief Financial Officer · Jan 6, 2025 – Jan 21, 2025 · Past) | Chief Financial Officer · Feb 8, 2024 – Feb 8, 2024 · Past |
| Ned MacPherson Other companies: MIRA Pharmaceuticals, Inc. (Director · Since at least Nov 4, 2026) | Director · Since at least Nov 4, 2026 |
| Talhia Tuck Other companies: MIRA Pharmaceuticals, Inc. (Director · Aug 2, 2023 – Aug 2, 2023 · Past) | Director · Feb 8, 2024 – Feb 8, 2024 · Past |
Log in to ask 6ix AI your own questions about Telomir Pharmaceuticals, Inc.